Views & Analysis Tunnah’s musings: Lessons for pharma from digital ASCO 2016 Pharma needs to remedy its approach to digital conference engagement.
Views & Analysis A European perspective on oncology: ASCO review An overview of the latest on immunotherapies, progress in multiple myeloma and benefits of patient-reported outcomes.
Views & Analysis Digital healthcare round-up: ASCO apps, public health, weara... A round-up of this week's top digital healthcare news. Marco Ricci reports.
News Potential lung cancer use for Novartis' melanoma combo New trial suggests use in lung cancer with same mutation.
Partner Content Partner Content Ibrance approval cemented as competition comes into view In February 2015, Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men
ASCO-slider Eye on ASCO Day 4 - Moonshots, Money and Mobile apps You don't often get searched by the US secret service at a medical meeting.
News Lilly plans Q1 2027 filing for obesity triple retatrutide Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
